IBD drug therapies and COVID-19
Institution or company
Cambridge University Hospitals NHS Foundation Trust
Gastroenterology, Infection, COVID
Our aim is to see whether the immunosuppressant drugs used to treat a high proportion of patients with IBD increase the risk of contracting COVID19, and/or whether they increase the risk of adverse outcomes for those who do become infected. The comparison will be against IBD patients on other drugs or none. The IBD BioResource participants have provided consent to access their health records, and this research will require a combination of a number of linked data sources – some of which need additional permissions.
Proposed data sources are: Public Health England (SARS-Cov2 test results, hospital admission and outcome); NHS Digital (hospital treatments); IBD Registry (the IBD Registry Risk Stratification Tool, patient-reported medications); and CPRD (primary care data), amongst others.